DE69736130D1 - Pharmazeutische produkte zur heilung und vorbeugung von krankheiten, die aus der beschädigung der vaskulären endothelzellen hervorgehen - Google Patents

Pharmazeutische produkte zur heilung und vorbeugung von krankheiten, die aus der beschädigung der vaskulären endothelzellen hervorgehen

Info

Publication number
DE69736130D1
DE69736130D1 DE69736130T DE69736130T DE69736130D1 DE 69736130 D1 DE69736130 D1 DE 69736130D1 DE 69736130 T DE69736130 T DE 69736130T DE 69736130 T DE69736130 T DE 69736130T DE 69736130 D1 DE69736130 D1 DE 69736130D1
Authority
DE
Germany
Prior art keywords
pct
endothelial cells
healing
prevention
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736130T
Other languages
English (en)
Other versions
DE69736130T2 (de
Inventor
Andrea Jednakovits
Laszlo Ueroegdi
Ede Marvanyos
Mihaly Barabas
Istvan Kurucz
Ernoe Bacsy
Laszlo Koranyi
Sandor Erdoe
Gyoergy Dorman
Marta Vitai
Gyoergy Schmidt
Marta Sinka
Magdolna Toeroek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
CytRx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU9602204A external-priority patent/HUP9602204D0/hu
Priority claimed from HU9701349A external-priority patent/HUP9701349A1/hu
Application filed by CytRx Corp filed Critical CytRx Corp
Publication of DE69736130D1 publication Critical patent/DE69736130D1/de
Application granted granted Critical
Publication of DE69736130T2 publication Critical patent/DE69736130T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69736130T 1996-08-09 1997-08-06 Pharmazeutische produkte zur heilung und vorbeugung von krankheiten, die aus der beschädigung der vaskulären endothelzellen hervorgehen Expired - Lifetime DE69736130T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
HU9602204A HUP9602204D0 (en) 1996-08-09 1996-08-09 Pharmaceutical compositions for treating diseases connected with the disfunction of the vascular endothelial cells
HU9602204 1996-08-09
HU9701349A HUP9701349A1 (hu) 1997-08-04 1997-08-04 Gyógyászati készítmények a vaszkuláris endoteliális sejtek rendellenes működésével összefüggő betegségek gyógyítására vagy megelőzésére
HU9701349 1997-08-04
PCT/HU1997/000044 WO1998006400A2 (en) 1996-08-09 1997-08-06 Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells

Publications (2)

Publication Number Publication Date
DE69736130D1 true DE69736130D1 (de) 2006-07-27
DE69736130T2 DE69736130T2 (de) 2007-01-04

Family

ID=90014231

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736130T Expired - Lifetime DE69736130T2 (de) 1996-08-09 1997-08-06 Pharmazeutische produkte zur heilung und vorbeugung von krankheiten, die aus der beschädigung der vaskulären endothelzellen hervorgehen

Country Status (20)

Country Link
US (1) US6143741A (de)
EP (1) EP0966283B1 (de)
JP (1) JP2001504446A (de)
AT (1) ATE329592T1 (de)
AU (1) AU739614B2 (de)
BG (1) BG64456B1 (de)
CA (1) CA2262997C (de)
CZ (1) CZ298542B6 (de)
DE (1) DE69736130T2 (de)
DK (1) DK0966283T3 (de)
EE (1) EE04044B1 (de)
ES (1) ES2267148T3 (de)
HK (1) HK1025506A1 (de)
IL (1) IL128256A (de)
NO (1) NO325109B1 (de)
PT (1) PT966283E (de)
RS (1) RS49719B (de)
SK (1) SK284301B6 (de)
UA (1) UA64716C2 (de)
WO (1) WO1998006400A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
HU226617B1 (en) * 1998-12-14 2009-04-28 Cytrx Corp Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
CA2471752A1 (en) 2002-01-11 2003-07-17 Biorex Kutato Es Fejlesztoe Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
EP2089033A2 (de) * 2006-12-01 2009-08-19 CytRx Corporation Erholung nach einer apoplexie
TW200901958A (en) * 2007-05-04 2009-01-16 Cytrx Corp Diabetic wound healing
JP5429865B2 (ja) * 2009-09-15 2014-02-26 学校法人日本大学 生体外創傷治癒試験用用具または創傷作製方法
HUP1100535A2 (en) * 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
WO2016201168A1 (en) * 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof
JP2024500632A (ja) 2020-11-19 2024-01-10 ゼブラ デンマーク エー／エス アリモクロモルクエン酸塩及びその中間体の調製プロセス

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187220A (en) * 1977-08-30 1980-02-05 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
GB9017351D0 (en) * 1990-08-08 1990-09-19 Wellcome Found Medicaments for treatment of atherosclerosis
CN1079789C (zh) * 1994-05-06 2002-02-27 拜奥列克斯研究发展公司 新的羟肟酸衍生物,包含它们的药物组合物及其制法
HU218480B (hu) * 1995-06-15 2000-09-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására

Also Published As

Publication number Publication date
WO1998006400A3 (en) 1998-03-26
EE04044B1 (et) 2003-06-16
NO325109B1 (no) 2008-02-04
US6143741A (en) 2000-11-07
EP0966283A2 (de) 1999-12-29
DK0966283T3 (da) 2006-10-09
NO990547L (no) 1999-03-25
ES2267148T3 (es) 2007-03-01
NO990547D0 (no) 1999-02-05
AU739614B2 (en) 2001-10-18
EE9900044A (et) 1999-08-16
SK284301B6 (sk) 2005-01-03
UA64716C2 (en) 2004-03-15
AU3704997A (en) 1998-03-06
SK15499A3 (en) 2000-02-14
HK1025506A1 (en) 2000-11-17
CZ43599A3 (cs) 1999-07-14
EP0966283B1 (de) 2006-06-14
IL128256A (en) 2004-05-12
BG103194A (en) 1999-09-30
CZ298542B6 (cs) 2007-10-31
JP2001504446A (ja) 2001-04-03
BG64456B1 (bg) 2005-03-31
WO1998006400A2 (en) 1998-02-19
ATE329592T1 (de) 2006-07-15
PT966283E (pt) 2006-08-31
CA2262997C (en) 2008-07-29
DE69736130T2 (de) 2007-01-04
RS49719B (sr) 2007-12-31
IL128256A0 (en) 2000-02-17
CA2262997A1 (en) 1998-02-19
YU5199A (sh) 2000-10-30

Similar Documents

Publication Publication Date Title
DE69706566D1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
DZ1794A1 (fr) Nouvelle formule pharmaceutique.
ATE178488T1 (de) Verfahren zur hemmung des knochenschwundes mit 3,4-diarylchroman
MD1507F2 (en) Inhibitors, pharmaceutical composition on base thereof and process for HIV protease inhibition
DE69736130D1 (de) Pharmazeutische produkte zur heilung und vorbeugung von krankheiten, die aus der beschädigung der vaskulären endothelzellen hervorgehen
NO20052739L (no) CCR5-antagonister som medikamenter
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
DE69019533D1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
YU79693A (sh) Inhibitori hiv proteaze korisni za lečenje aidsa-a
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
GEP20053617B (en) Bridged Piperazine Derivatives
DE69525649D1 (de) Lamotrigin haltiges arzneimittel
ATE281162T1 (de) Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose
ATE184793T1 (de) Die verwendung von carbostyrilderivaten zur herstellung eines arzneimittels zur hemmung der produktion von interleukin-8
DE69828615D1 (de) Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
IT1284873B1 (it) Derivati stabili di ubichinolo procedimenti per la loro produzione e loro impiego farmaceutico
ATE190484T1 (de) Arzneimittel zur behandlung von durch babesia verursachten protozoeninfektionen
DE69312297D1 (de) Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs
ATE190845T1 (de) Rektale flunisolid-zubereitung zur behandlung entzündlicher darmerkrankungen
ATE300304T1 (de) Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose
DE69429538D1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen
PT1165596E (pt) Derivados de 14,15-alfa-metileno equilenina processos para producao dos mesmos e medicamentos que os contem
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition